NASDAQ: CVACCurevac Nv Stock
$2.33+0.02 (+0.87%)
Updated Apr 26, 2024
CVAC Price
$2.33
Fair Value Price
N/A
Market Cap
$521.89M
52 Week Low
$2.22
52 Week High
$12.36
P/E
-1.84x
P/B
0.94x
P/S
15.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.80M
Earnings
-$289.07M
Gross Margin
-131.3%
Operating Margin
-478.95%
Profit Margin
-484%
Debt to Equity
0.53
Operating Cash Flow
-$298M
Beta
1.25
Next Earnings
Jun 18, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CVAC Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CVAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVAC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVAC is good value based on its book value relative to its share price (0.94x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
CVAC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CVAC due diligence checks available for Premium users.
Be the first to know about important CVAC news, forecast changes, insider trades & much more!
CVAC News
Valuation
CVAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.84x
Industry
14.88x
Market
41.14x
CVAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.94x
Industry
5.85x
CVAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVAC's financial health
Profit margin
Revenue
$25.1M
Net Income
-$96.3M
Profit Margin
-384%
CVAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CVAC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$875.8M
Liabilities
$301.5M
Debt to equity
0.53
CVAC's short-term assets ($514.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVAC's short-term assets ($514.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CVAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$48.5M
Investing
-$16.0M
Financing
-$1.6M
CVAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CVAC vs Biotech Stocks
Curevac Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.